Assetmark Inc. Has $8.30 Million Stock Position in Novo Nordisk A/S $NVO

Assetmark Inc. lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 4.9% in the 1st quarter, Holdings Channel.com reports. The fund owned 225,788 shares of the company’s stock after selling 11,608 shares during the period. Assetmark Inc.’s holdings in Novo Nordisk A/S were worth $8,298,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of NVO. Revolve Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the period. AQR Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after buying an additional 10,758 shares during the period. Sivia Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after acquiring an additional 1,587 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after acquiring an additional 87,467 shares during the period. Finally, Gamco Investors INC. ET AL acquired a new position in shares of Novo Nordisk A/S in the second quarter worth approximately $314,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $49.61 on Tuesday. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $71.79. The business’s fifty day moving average is $46.16 and its 200 day moving average is $45.78. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock has a market cap of $221.52 billion, a P/E ratio of 11.65, a P/E/G ratio of 4.59 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion during the quarter. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday. Finally, HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: European regulators approved Wegovy as the first GLP-1 obesity tablet, giving Novo Nordisk a new oral option that could expand the company’s reach beyond injectable treatments. Wegovy Pill in Europe – Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
• Positive Sentiment: Citi raised its price target on Novo Nordisk ahead of Q2 results, citing strong Wegovy pill launch trends and lifting its sales and earnings estimates for the next several years. Citi lifts Novo Nordisk target on strong GLP-1 pill launch
• Positive Sentiment: Prescription data cited in recent commentary suggests oral Wegovy is gaining traction quickly in the U.S., with most new scripts coming from patients new to GLP-1 therapy, which could mean market expansion rather than cannibalization. Novo Nordisk’s Rally Has Room To Run Driven By Oral Wegovy’s Momentum
• Positive Sentiment: Novo Nordisk also expanded its diabetes portfolio in China by launching Kyinsu through Fangzhou’s AI-driven Internet hospital platform, potentially improving access and adding another growth channel. Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
• Neutral Sentiment: Analysts and media commentary note that while the Wegovy pill improves Novo’s product mix, the company still faces intense competition in the GLP-1 market, keeping the longer-term outlook mixed. Does EU Approval of Wegovy Pill Change NVO’s Competitive Story?
• Neutral Sentiment: Novo Nordisk also continued its share repurchase program, which can support the stock, but this is a routine capital-allocation update rather than a major new catalyst. Novo Nordisk A/S – share repurchase programme

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.